随着越来越多的新能源汽车进入二手车市场以及陆续脱离8年质保期，由动力电池老龄化引发的消费焦虑也在与日俱增。为此，一些保险公司、行业 企业试图通过业务和产品创新，来破解消费者关于动力电池寿命的焦虑。 今年1月，金融监管总局、工信部等4部门出台《关于深化改革加强监管促进新能源车险高质量发展的指导意见》提出，支持保险行业围绕新能源汽车 商业车险保障需求，创新优化新能源车险供给。 其实去年12月，人保财险四川省分公司和宁德时代合作，在四川落地了首单"新能源汽车动力电池容量保障保险"，对二手新能源汽车的动力电池进行 保障。当动力电池在约定的保险期限或行驶公里数内，达到约定的衰减率时，保险公司将对动力电池进行更换或维修。 电池衰减险方兴未艾 近年来，新能源汽车产业蓬勃发展，市场前景一片向好。受此影响，新能源二手车市场也迎来快速增长期，今年前5个月新能源二手车交易量突破50 万辆，但与此同时面临的严峻挑战却不容忽视，特别是动力电池保障困境成为行业发展的"绊脚石"。目前，主流车企提供整车或三电质保，大多仅适用于 首任车主，一旦车辆过户后超出质保期，动力电池健康保障便处于"裸奔"状态。这种状况不仅让消费者在选购新能源二手车时顾 ...

云南白药集团股份有限公司 2、药品事业群 2024 年经营情况如何？ 答：2024 年药品事业群主营业务收入 69.24 亿元，同比增长 11.8%， 单品销售过亿产品达 10 个。核心系列产品中，云南白药气雾剂销售 收入突破 21 亿元，同比增长超 26%；云南白药膏、云南白药胶囊、 云南白药创可贴、云南白药（散剂）均在上年销售收入基础上，实现 显著增长。其他品牌中药类产品增长亮眼，蒲地蓝消炎片销售收入近 2 亿元，同比大幅增长超 22%，血塞通胶囊、小儿宝泰康颗粒、参苓 健脾胃颗粒产品收入均破亿。植物补益类产品，气血康口服液销售收 入继续保持增长态势，同口径下同比增长约 14%。 投资者调研会议记录 时间：2025 年 7 月 9 日 地点：集团总部办公大楼 召开方式：现场调研 投资者：平安基金-王华、丁琳，信达证券-章钟涛、王留阳 参加人员：投资者关系管理-张昱、杨可欣 会议内容 1、请问公司 2025 年一季度业绩情况如何？ 答：2025 年第一季度，公司实现营业收入 108.41 亿元，同比增 长 0.62%；归母净利润 19.35 亿元，同比增长 13.67%；扣非归母净利 润 18.87 亿元， ...

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company is expected to achieve a net profit of 368-388 million yuan in H1 2025, representing a year-on-year increase of 24%-31% [1] - The strategic upgrade towards a consumer-oriented approach is expected to enhance the company's market position and product competitiveness [3] - The company has adjusted its profit forecasts for 2025 and 2026 downwards due to uncertainties in product volume post-hospital procurement [4] Summary by Sections Financial Performance - For H1 2025, the company anticipates a net profit of 368-388 million yuan, with a growth rate of 25%-32% for the non-recurring net profit [1] - The operating cash flow is projected to be between 270-290 million yuan, reflecting a year-on-year increase of 25%-35% [1] - In Q2 2025, the expected net profit is between 187-207 million yuan, with a year-on-year growth of 21%-34% [1] Revenue and Profitability - The core products are experiencing steady growth, with sales of specific products like Wuling Capsules and Lingze Tablets continuing to perform well [2] - The overall revenue growth in Q2 2025 is estimated at 3%, attributed to a decline in traditional Chinese medicine sales [2] - The net profit margin for H1 2025 is expected to increase by 2.3-3.5 percentage points due to a shift in revenue structure and cost control measures [2] Strategic Initiatives - The company has launched a strategic upgrade termed "一路向 C" (Towards C), focusing on optimizing OTC business and developing innovative health products [3] - A strategic partnership with Zhejiang University aims to leverage AI technology for developing health management products, enhancing the company's technological edge [3] Earnings Forecast and Valuation - The profit forecasts for 2025 and 2026 have been adjusted to 655 million yuan and 836 million yuan respectively, reflecting a decrease of 4.8% and 5.6% from previous estimates [4] - The projected P/E ratios for the upcoming years are 20, 16, and 12 for 2025, 2026, and 2027 respectively [4]

Core Viewpoint - The article emphasizes the importance of eye care for children during the summer vacation, highlighting the risks of increased screen time and irregular routines that can lead to vision deterioration. It advocates for regular eye check-ups and preventive measures to maintain children's vision health [1][4]. Group 1: Vision Health Statistics - In 2022, the overall myopia rate among children and adolescents in China was reported at 51.9%. Despite a downward trend in myopia rates, early onset and high prevalence remain significant challenges [1]. - The concept of "vision savings" is introduced, where the reserve of hyperopia (farsightedness) serves as a buffer against developing myopia [2]. Group 2: Importance of Regular Eye Check-ups - Regular professional eye examinations are crucial for establishing visual health records, which include key indicators such as hyperopia reserve, myopia degree, and axial length [4]. - A low hyperopia reserve relative to age norms indicates an increased risk of myopia, even if the child's vision appears normal [4]. Group 3: Preventive Measures for Eye Health - Four key strategies are recommended for parents to help children maintain clear vision and slow the progression of myopia: 1. Balance study and rest, maintain proper reading posture, and improve lighting conditions. 2. Follow the "20-20-20" rule to reduce eye strain. 3. Engage in outdoor activities for at least 2 hours daily, totaling 14 hours weekly, as outdoor light exposure is critical for myopia prevention. 4. Ensure a balanced diet and adequate sleep, which are essential for children's growth and eye health [6]. Group 4: Standards for Lighting Conditions - The National Health Commission's "Myopia Prevention and Control Guidelines (2024 Edition)" specifies that reading and writing should occur in well-lit environments, with a minimum average illuminance of 300 lux [8]. Group 5: Caution Against Misleading Products - There is a growing concern regarding products claiming to reverse myopia, which are often misleading. True myopia is currently considered irreversible by experts [9]. - Since 2021, the State Administration for Market Regulation has been addressing misleading advertising related to myopia prevention products, emphasizing that myopia cannot be cured under current medical conditions [9].

在港股IPO持续升温的背景下，医疗支付领域迎来重要参与者。 6月30日，上海镁信健康科技集团股份有限公司（下称"镁信健康"）正式向香港联交所递交招股说明书，拟赴港上市。 简单来说，镁信健康的核心模式在于推动医疗健康与保险融合。公司致力于解决患者、保司与药企面临的筹资与支付挑战，实现医疗体系相关各方的协 同。 截至去年年底，镁信健康累计服务了约160万名患者，与超140家药企以及超90家保险公司达成合作。 回顾镁信健康的融资历程，其先后完成七轮融资，估值从Pre-A轮的1.5亿元一路飙升至C+轮的约116.78亿元，增幅达77倍。此次IPO不仅是企业发展的重 要里程碑，也为行业发展轨迹增添了新的观察维度。 39岁创始人，带队冲击IPO 故事要从2017年说起，镁信健康由张小栋与上海医药大健康创立。 张小栋发现，在医保"保基本"定位下，创新药、特药价格昂贵且需"自费"，这像一堵墙横亘在市场和患者之间。 "让患者用得起、用得上好药"，便成了张小栋创立镁信健康的初心。"我们不是去跟风追求某个模式，而在于看到老百姓生病之后，除了医保，没有其他 渠道可以支付，几乎都是他们自费。" 镁信健康成立后的第一款产品，是与药企合作 ...

Core Viewpoint - The Tianyue Kangkang AI smart ring represents an innovative solution in the wearable health monitoring sector, integrating CBT-I (Cognitive Behavioral Therapy for Insomnia) for comprehensive sleep management [1][11]. Group 1: Product Features - The smart ring is designed for comfort, with a thickness of only 2.5mm and a weight of 3 grams, made from aerospace-grade metal, available in three colors [4]. - It offers a "no-sense wear" experience, making it more comfortable for continuous use, especially during sleep, compared to traditional smartwatches [4]. - The product includes a free finger size kit to ensure accurate fitting, enhancing the accuracy of health monitoring [8]. Group 2: Monitoring Capabilities - The smart ring provides real-time monitoring of vital signs such as heart rate, blood oxygen, body temperature, and HRV (Heart Rate Variability), generating a dynamic health baseline through AI algorithms [9][10]. - It boasts high monitoring accuracy, comparable to the well-known Oura Ring, and can capture short naps exceeding 15 minutes [10]. Group 3: Sleep Management - The product incorporates a four-dimensional sleep improvement plan based on the CBT-I framework, offering detailed sleep data recording [11]. - It features an AI-driven sleep aid function that recommends specific sound frequencies to enhance deep and REM sleep quality [11]. Group 4: Elderly Care Features - The smart ring includes a fall detection warning system, analyzing key indicators to predict potential fall risks in elderly users [15]. - It allows family members to remotely monitor the health data of their elderly relatives, facilitating proactive health management [15]. - The integration of a personalized health model enhances its competitive edge in the elderly health sector [15]. Group 5: Market Positioning - The Tianyue Kangkang AI smart ring redefines health management in wearable devices, focusing on both fall prevention and sleep improvement, making it particularly appealing to users concerned about the health of their elderly family members [15].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们 的推送。 7月9日， 北京市科学技术委员会、中关村科技园区管理委员会联合发布了 《2025年北京市 重点实验室申报指南》 ，为方便广大实验室申请，本文简单介绍 北京市重点实验室的 评审标 准 供参考： 小编根据北京市重点实验室的相关政策及申报指南， 简单梳理了 北京市重点实验室的 评 审 标 准 及 申报策略建议 供 参考 ： 一、基础条件评审标准 依托单位资质 须为北京市内注册的企业、事业单位或社会组织法人，且近三年无重大失信、安全生产事故等 不良记录（）。 科研条件：科研用房面积不低于1000平方米，科研仪器设备原值不低于1500万元（新领域可 适当放宽）。 企业单位要求： 近3年年均销售收入≥10亿元，研发费用占比≥5%； 或年均研发费用≥2亿元（技术含量高、投资周期长的企业）； 研发费用境内占比≥60%。 研究方向与任务 研究方向需符合北京市重点领域发展需求（如智能制造、新一代信息技术、生物医药等），聚 焦"卡脖子"技术或关键共性技术。 能凝练科学问题或技术难题，提出切实可行的任务目标和技术路 ...

高纯度 Omega-3丨 白皮书 核心摘要： 在健康中国战略全面推进的背景下，国民健康管理意识显著提升，健康需求从 "被动治疗"向"主动预防"加 速转型。随着慢性病防控与亚健康改善成为全民健康的核心议题，膳食营养补充剂已成为全民健康管理的重 要工具，其市场发展与科学认知深化同步推进。基于这一现状，本白皮书旨在深入探讨高纯度 Omega-3 在中国居民健康管理中的作用及应用现状，加强公众对其生理功效的认知，为公众提供更加专业的营养指 导。白皮书从以下五个章节展开： 一、中国居民健康管理现状 国家政策推动全民健康管理向主动预防转型，面对慢性病年轻化与全周期防护挑战，需构建监测、干预与营 养支持体系。膳食营养补充剂通过定向支持和免疫力提升，成为公众践行主动健康管理的核心工具，助力实 现从治疗到预防的跨越。 二、膳食营养补充剂市场认知及应用表现 在国民健康管理需求升级与膳食营养补充剂市场快速发展的双轮驱动下，服用膳食营养补充剂已进阶为现代 人健康管理的核心方案。在消费者决策矩阵中，产品本身与品牌背书构成购买双引擎。但不同人群对成分需 求呈现差异化特征，折射精准健康管理趋势。 三、 Omega-3 产品与应用现状 Om ...

近年来，随着家长对儿童健康关注度的持续提升，益生菌作为调节肠道微生态、增强免疫力的功能性营 养素，在儿童健康产品市场中迅速崛起。 据共研产业研究院数据，2024年中国儿童益生菌市场规模已达到420.47亿元，预计到2028年将增长至 509.88亿元，年复合增长率约为4.94%。为了更易被儿童接受，益生菌的产品形态也在不断进化，出现 了诸如软糖、粉末、液体等多种形式的产品，满足了不同年龄段儿童的需求。在市场竞争方面，国内外 品牌纷纷布局儿童益生菌领域，进口的高质量的儿童益生菌产品受到家长的青睐。 同时，国产品牌也在加快研发步伐，利用本土菌株优势，推出更适合中国儿童肠道特点的益生菌产品。 其中赛哺高作为儿童微生态健康领域的先锋品牌，凭借在儿童身高干预领域的创新成果与科研实力在近 些年屡获殊荣，在前不久的"510中国品牌日"更是被授予"儿童成长益生菌行业领先品牌"，品牌实力得 到权威认可。 赛哺高能够获此殊荣并非偶然。一方面，赛哺高在科研投入上不遗余力，组建了一支由顶尖微生物学专 家、营养学专家等构成的专业研发团队，长期致力于儿童益生菌配方的优化与创新。他们深入研究儿童 肠道菌群的独特性，发现在诸多因素中，"肠道 ...

于欣丽理事长强调：面对我国超重肥胖这一重大公共卫生挑战，国家将2025年定为"体重管理年"，是贯 彻健康优先战略、推进慢性病防控关口前移的关键举措。此次大会以落实国家"体重管理年"行动为核 心，通过增补卫生健康专委会成员、成立专业编委会、凝聚多领域力量，聚焦健康体重管理标准化体系 构建，凸显标准化在实现服务同质化高质量、促进技术创新与规范应用、推动多方协同资源整合、强化 科学监管与持续改进及培育专业化人才中的核心引擎作用，旨在以标准为引领，系统破解体重管理领域 痛点，为全民健康筑牢根基，助力健康中国战略落地见效。 韩凌雁秘书长在双平台协同工作汇报中提到，卫生健康专委会此次增补历经严格的选举和审核流程，在 健康体重管理方向，由中国医学科学院北京协和医院陈伟教授担任副主任委员组建起近百人的复合型专 业团队，涵盖临床诊疗、科研创新与行业管理的方面。同期成立的《中国卫生标准管理》杂志健康体重 管理编辑委员会，聘任陈伟教授为第一届主编，陈君石院士担任名誉主编，多位顶尖专家组成顾问团， 为标准成果的应用与传播奠定核心支撑。 来自全国医疗机构、高校的临床营养、内分泌、外科、心血管、公共卫生、健康管理、运动医学及标准 化研究 ...